American drug maker ArQule Inc revealed that its experimental colorectal cancer drug, developed in collaboration with Japan's Daiichi Sankyo Co Ltd, has failed to achieve its main goal of extending the progression-free survival period in patients in a trial.
The experimental drug, known as tivantinib, was ArQule's lead candidate with the company also hoping that the drug could be used in treating hepatocellular carcinoma or liver cancer.
The company said that while the drug was able to slightly improve the progression free survival period in the trial, which included 122 patients with refractory or relapsed colorectal cancer, the improvement was not significant enough.
Daiichi's Reinhard von Roemeling tried to remain positive, stating that they will now be looking at how to best proceed in improving the drug. "We are encouraged by these findings. We plan to continue discussions to determine how best to proceed with further clinical development of tivantinib in this tumor type", he said.